Answers are grounded in this paper and cite their sources.
the Journal of Clinical Oncology requires comment to permit accurate scientific perspective. In contrast to the statement "we are not aware of any published reports from the large, single institutions, reporting outcome for these patients (metachronous skeletal osteosarcoma) when treated with a combined modality treatment approach," the experience of post-therapy multiple metachronous primary osteosarcoma tumors in the pediatric population was presented in a general poster session at the annual meeting of the American Society of Clinical Oncology in May 2001. 2 The abstract presented data on 11 pediatric patients, following a review of 250 patients under 18 years of age, who presented to the M.D. Anderson Cancer Center (Houston, TX) with primary osteosarcoma of the skeleton without pulmonary metastases over the past 25 years. The interval between appearance of the primary and metachronous tumor varied from 12 to 78 months. Inter alia, the abstract addressed the concordance and discordance of the histologic varieties of the primary and metachronous tumors and referred to a possible increased incidence of the condition in patients with retinoblastoma.
No takes yet. Share an insight, caveat, or question.
Cuzick et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: